Annual report
4531.TEDINET S100TQ3M
Period2023-04-01 → 2024-03-31
Filed2024-06-24
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 88
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.9bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥12.8bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥12.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥11.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥10.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥897m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.1bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥660m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥397m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥176m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥401m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥905m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥641m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥776m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥556m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥248m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥288m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥42m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥24.4bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥22.1bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥21.2bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥21.0bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥20.2bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥11.9bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥10.6bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥12.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.5bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.0bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥10.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥10.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥588m | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥588m | at 2024-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2022-03-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2021-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.4bn | at 2020-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥388m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥668m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥352m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥442m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥648m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥315m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥948m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥158m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥772m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥106m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥992m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥35.57 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.51 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥11.37 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.22 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.97 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥8 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥7 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥4 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥2 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥569.6 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥525.98 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥504.23 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥501.55 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥482.75 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 51.0% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.9% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.5% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.4% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 21,974,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,974,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,974,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,974,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,974,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 290 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 295 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 296 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 303 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 309 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 1
| Segment | Item | Period | Value |
|---|---|---|---|
| Fine Chemical Businessreportable segment | employees | at 2024-03-31 | 290 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,058
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | Original text (Japanese)株式分割 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)ゼリア新薬工業株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)医薬品関係で取引があり、同社との営業上の関係強化のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)あすか製薬ホールディングス株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)医薬品関係で取引があり、同社との関係強化のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)住友商事株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)アミノ酸関係、化成品関係、医薬品関係で取引があり、同社との関係強化のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)株式会社大阪ソーダ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)医薬品関係で取引があり、今後更なる同社との関係強化のため、当事業年度より同社株式を保有しました。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)株式会社三菱UFJフィナンシャル・グループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)融資等で取引があり、同社との関係強化のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)株式会社クレハ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)ニプロ株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)医薬品関係で取引があり、同社との業務提携及び資本提携のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)株式会社めぶきフィナンシャルグループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)融資等で取引があり、同社との関係強化のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)久光製薬株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)医薬品関係で取引があり、同社との関係強化のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)住友ファーマ株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)医薬品関係で取引があり、同社との関係強化のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)株式会社東京きらぼしフィナンシャルグループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)融資等で取引があり、同社との関係強化のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)広栄化学株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)化成品関係で取引があり、同社との関係強化のため、同社株式を保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)有 | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that consolidated financial statements have not been prepared financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Statement of income (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |